EJNMMI Research

Papers
(The H4-Index of EJNMMI Research is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Nanobody: a promising toolkit for molecular imaging and disease therapy93
Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review38
Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis35
A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinson’s disease32
Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics28
Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based on 18F-FDG PET/CT radiomics27
External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients25
Deep learning-based amyloid PET positivity classification model in the Alzheimer’s disease continuum by using 2-[18F]FDG PET24
Preliminary study of AI-assisted diagnosis using FDG-PET/CT for axillary lymph node metastasis in patients with breast cancer23
The pons as reference region for intensity normalization in semi-quantitative analysis of brain 18FDG PET: application to metabolic changes related to ageing in conventional and digital control databa23
CERMEP-IDB-MRXFDG: a database of 37 normal adult human brain [18F]FDG PET, T1 and FLAIR MRI, and CT images available for research22
Normal values for 18F-FDG uptake in organs and tissues measured by dynamic whole body multiparametric FDG PET in 126 patients22
Imaging modalities for diagnosis and monitoring of cancer cachexia21
First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer21
The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.020
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer20
The value of 18F-PSMA-1007 PET/CT in identifying non-metastatic high-risk prostate cancer20
Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network19
Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer19
0.087249994277954